Volltext-Artikel, E-Books und Literaturhinweise aus dem EBSCO Discovery Service

"Artikel & mehr" berücksichtigt nur einen Teil der für die Bibliothek der Frankfurt UAS verfügbaren Datenbanken. Zur Übersicht in DBIS

Ergebnis verändern

einschränken: Volltextzugriff; Academic (peer-reviewed) journals
erweitern: Auch Volltexte der Artikel durchsuchen; Verwandte Themen suchen

Publikationstyp

Thema

erschienen in

Verlag

Geographic terms

Sprache

Datenbank

mehr ...

Erscheinungsjahr

Von:

Bis:

Treffer 1 - 25 von 396, Suchdauer: 0.7s

12 3 4 5 6 7 8 9 10 11 weiter »

1
Linavonkibart and pembrolizumab in immune checkpoint blockade-resistant advanced solid tumors: a phase 1 trial

von Yap, Timothy A. ; Sweis, Randy F. ; Vaishampayan, Ulka ; et al.

Nature Medicine. 32(3):992-1001
- Volltextverfügbarkeit prüfen (via ReDI)
Merkliste

2
High tumor glucocorticoid receptor expression in early-stage, triple-negative breast cancer is associated with increased T-regulatory cell infiltration

von Matossian, Margarite D. ; Shiang, Christine ; Dolcen, Deniz Nesli ; et al.

Breast Cancer Research and Treatment. 209(3):563-572
- Zum Volltext (via ReDI)
Merkliste

3
Dieses Ergebnis aus Science Citation Index Expanded kann Gästen nicht angezeigt werden.
Login für vollen Zugriff.
- Zur Referenz in Web of Science
Merkliste

4
609 Restoring immune responsiveness in periphery and tumor with mRNA-4359, an mRNA-based therapy encoding PD-L1 and IDO1 peptides, plus pembrolizumab in checkpoint inhibitor resistant/refractory melanoma

von Sarker, Debashis ; Long, Georgina ; Pinato, David J ; et al.

Regular and Young Investigator Award Abstracts ; page A694-A694
- View full text via BASE
Merkliste

5
A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma

von Msaouel, Pavlos ; Sweis, Randy F. ; Bupathi, Manojkumar ; et al.

In European Urology Oncology August 2024 7(4):933-943
- View full text via DOI
Merkliste

6
482 Deciphering mediators of PD-1/PD-L1 blockade efficacy in bladder cancer and the role of FGFR3 in immunotherapy resistance

von Ziblat, Andrea ; Hatogai, Ken ; Fernald, Anthony A ; et al.

Regular and Young Investigator Award Abstracts ; page A548-A548
- View full text via BASE
Merkliste

7
Batf3+ DCs and the 4-1BB/4-1BBL axis are required at the effector phase in the tumor microenvironment for PD-1/PD-L1 blockade efficacy

von Ziblat, Andrea ; Horton, Brendan L. ; Higgs, Emily F. ; et al.

In Cell Reports 28 May 2024 43(5)
- View full text via DOI
Merkliste

8
Dieses Ergebnis aus Science Citation Index Expanded kann Gästen nicht angezeigt werden.
Login für vollen Zugriff.
- Zur Referenz in Web of Science
Merkliste

9
Primary site stereotactic ablative body radiotherapy in localized, recurrent, and metastatic renal cell carcinoma

von Huang, Daniel ; Lynch, Connor ; Serra, Lucas M. ; et al.

In Clinical and Translational Radiation Oncology November 2024 49
- View full text via DOI
Merkliste

10
A phase 1b open-label study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of py314 in combination with pembrolizumab in patients with advanced renal cell carcinoma

von Beckermann, Kathryn E. ; Patnaik, Amita ; Winer, Ira ; et al.

Investigational New Drugs: Novel Anti-Cancer Therapeutics and Therapies. 42(2):179-184
- Zum Volltext (via ReDI)
Merkliste

11
Bladder-Preserving Trimodality Therapy With Capecitabine

von Lynch, Connor ; Sweis, Randy F. ; Modi, Parth ; et al.

In Clinical Genitourinary Cancer April 2024 22(2):476-482
- View full text via DOI
Merkliste

12
Intratumoral or Subcutaneous MK-2118, a Noncyclic Dinucleotide STING Agonist, with or without Pembrolizumab, for Advanced or Metastatic Solid Tumors or Lymphomas

von Luke, Jason J ; Sweis, Randy F ; Hecht, J Randolph ; et al.

Clinical Cancer Research, vol 31, iss 7

Schlagworte: 32 Biomedical and Clinical Sciences (for-2020); 3202 Clinical Sciences (for-2020); 3211 Oncology and Carcinogenesis (for-2020); Immunotherapy (rcdc); Clinical Research (rcdc); Clinical Trials and Supportive Activities (rcdc); Cancer (rcdc); 6.1 Pharmaceuticals (hrcs-rac); Humans (mesh); Antibodies; Monoclonal; Humanized (mesh); Female (mesh); Male (mesh); Middle Aged (mesh); Aged (mesh); Lymphoma (mesh); Adult (mesh); Neoplasms (mesh); Antineoplastic Combined Chemotherapy Protocols (mesh); Membrane Proteins (mesh); Aged; 80 and over (mesh); Injections; Subcutaneous (mesh); Treatment Outcome (mesh)
- View full text via BASE
Merkliste

13
Melanoma and microbiota: Current understanding and future directions

von Routy, Bertrand ; Jackson, Tanisha ; Mählmann, Laura ; et al.

In Cancer Cell 8 January 2024 42(1):16-34
- View full text via DOI
Merkliste

14
The current and future role of systemic therapy in non–muscle‐invasive bladder cancer

von Lazarovich, Alon ; Sweis, Randy F.

Cancer ; volume 131, issue 13 ; ISSN 0008-543X 1097-0142
- View full text via BASE
Merkliste

15
Mathematical model predicts tumor control patterns induced by fast and slow cytotoxic T lymphocyte killing mechanisms

von Yixuan Wang ; Daniel R Bergman ; Erica Trujillo ; et al.

Scientific Reports, Vol 13, Iss 1, Pp 1-12 (2023)

Schlagworte: Medicine; Science
- View full text via DOI
Merkliste

16

Dieses Ergebnis aus CINAHL kann Gästen nicht angezeigt werden.
Login für vollen Zugriff.

Merkliste

17
The Development of STING Agonists and Emerging Results as a Cancer Immunotherapy

von Hines, Jacobi B. ; Kacew, Alec J. ; Sweis, Randy F.

Current Oncology Reports. 25(3):189-199
- Zum Volltext (via ReDI)
Merkliste

18
Dysregulated FGFR3 signaling alters the immune landscape in bladder cancer and presents therapeutic possibilities in an agent-based model

von Daniel R. Bergman ; Yixuan Wang ; Erica Trujillo ; et al.

Frontiers in Immunology, Vol 15 (2024)

Schlagworte: agent-based model; bladder cancer; FGFR3; immune checkpoint inhibition; CD8+ T cells; Fas/Fas ligand; Immunologic diseases. Allergy; RC581-607
- View full text via DOI
Merkliste

19
Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study

von Lee, Chung-Han ; Shah, Amishi Yogesh ; Rasco, Drew ; et al.

In The Lancet Oncology July 2021 22(7):946-958
- View full text via DOI
Merkliste

20
A global method for fast simulations of molecular dynamics in multiscale agent-based models of biological tissues

von Bergman, Daniel ; Sweis, Randy F. ; Pearson, Alexander T. ; et al.

In iScience 17 June 2022 25(6)
- View full text via DOI
Merkliste

21
Germline genetic contribution to the immune landscape of cancer

von Sayaman, Rosalyn W. ; Saad, Mohamad ; Thorsson, Vésteinn ; et al.

In Immunity 9 February 2021 54(2):367-386
- View full text via DOI
Merkliste

22
Pembrolizumab in Combination With Gemcitabine and Concurrent Hypofractionated Radiation Therapy as Bladder-sparing Treatment for Muscle-invasive Urothelial Cancer of the Bladder: A Multicenter Phase 2 Trial

von Economides, Minas P. ; O’Donnell, Peter H. ; Alva, Ajjai S. ; et al.

In European Urology February 2026
- View full text via DOI
Merkliste

23
Novel Immunotherapies and Novel Combinations of Immunotherapy for Metastatic Melanoma

von Olson, Daniel J. ; Gutierrez, Rodolfo ; Bentebibel, Salah Eddine ; et al.

Cutaneous Melanoma. :1165-1186
- Volltextverfügbarkeit prüfen (via ReDI)
Merkliste

24
Dieses Ergebnis aus Science Citation Index Expanded kann Gästen nicht angezeigt werden.
Login für vollen Zugriff.
- Zur Referenz in Web of Science
Merkliste

25
Morphological correlation of urinary bladder cancer molecular subtypes in radical cystectomies

von Han, Lisa ; Gallan, Alexander J. ; Steinberg, Gary D. ; et al.

In Human Pathology December 2020 106:54-61
- View full text via DOI
Merkliste

12 3 4 5 6 7 8 9 10 11 weiter »

Sie haben nicht gefunden, wonach Sie gesucht haben? Diese Services können Ihnen weiterhelfen.
Hilfe & Kontakt ǀ Fernleihe | Hilfe zur Fernleihe ǀ Literaturvorschlag| Literaturvorschlag